Bosutinib – an effective and safe treatment option in the management of chronic myeloid leukemia

Molecular dynamics simulations of the conformational plasticity in the active pocket of salt-inducible kinase 2 (SIK2) multi-state binding with bosutinib

“…Bosutinib was selected as the template inhibitor for SIK2. Bosutinib, which is a Food and Drug Administration (FDA)-approved pan-kinase inhibitor, can inhibit SIK2 from the screening potential SIK2 inhibitors in vitro [ [44] , [45] , [46] ]. Bosutinib ( Fig.…”

Bosutinib – related pleural effusion in patients with chronic myeloid leukemia

“…Bosutinib is another potent 2GTKI, which can also be used in the first-and subsequent-lines in patients with CML [20]. It is a dual Src/Abl TKI, and it exhibits minimal inhibitory activity against c-KIT or PDGFR [21].…”

Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?

“…As a difference in the recent recommendations, bosutinib is included for the treatment of CML in chronic-phase (CML-CP) in the upfront setting [4]. This follows the data from the BFORE trial published in 2018 that compares bosutinib to imatinib in newly diagnosed CML-CP patients [10,11]. The panel recognized radotinib [12] and its randomized comparison with imatinib in Korea [13] but, concluded that further information is needed for this drug before its universal recommendation for treatment.…”